 The objective of the study is to investigate whether RNF treatment initiated after the first clinical event versus delayed treatment results in the prolongation of time to Clinically Definite Multiple Sclerosis CDMS conversion up to Month 36 and up to Month 60 since randomization in Study 27025 REFLEX. Furthermore, the study is intended to explore whether RNF treatment initiated after the first clinical event versus delayed treatment delays disability including development of secondary progressive MS and reduces disease activity including the annual relapse rate ARR in the long term up to Month 36 and up to Month 60 since randomization in Study 27025 REFLEX. The study will also assess the long-term safety profile of RNF up to Month 36 and up to Month 60 since randomization in Study 27025 REFLEX. 